NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) was downgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued on Wednesday,Zacks.com reports.
Several other equities analysts have also weighed in on NRXP. UBS Group restated a “buy” rating on shares of NRx Pharmaceuticals in a report on Wednesday. Wall Street Zen lowered shares of NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. HC Wainwright reiterated a “buy” rating on shares of NRx Pharmaceuticals in a research report on Tuesday. BTIG Research reissued a “buy” rating and issued a $10.00 price target on shares of NRx Pharmaceuticals in a research note on Tuesday, August 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research report on Wednesday, August 5th. Five investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, NRx Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $34.50.
Check Out Our Latest Stock Report on NRXP
NRx Pharmaceuticals Trading Up 4.6%
NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) last issued its earnings results on Monday, August 17th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.33). The firm had revenue of $1.10 million for the quarter, compared to the consensus estimate of $1.33 million. Research analysts forecast that NRx Pharmaceuticals will post -0.36 EPS for the current year.
Institutional Trading of NRx Pharmaceuticals
A number of hedge funds have recently modified their holdings of the company. Ethos Financial Group LLC increased its position in shares of NRx Pharmaceuticals by 33.6% in the 1st quarter. Ethos Financial Group LLC now owns 15,900 shares of the company’s stock valued at $34,000 after buying an additional 4,000 shares in the last quarter. State Street Corp raised its stake in NRx Pharmaceuticals by 14.0% during the 4th quarter. State Street Corp now owns 86,984 shares of the company’s stock worth $236,000 after buying an additional 10,700 shares during the period. Two Sigma Investments LP raised its stake in NRx Pharmaceuticals by 66.4% during the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after buying an additional 20,880 shares during the period. Geode Capital Management LLC lifted its holdings in NRx Pharmaceuticals by 17.8% during the fourth quarter. Geode Capital Management LLC now owns 218,866 shares of the company’s stock worth $593,000 after acquiring an additional 33,004 shares in the last quarter. Finally, Global Retirement Partners LLC bought a new position in NRx Pharmaceuticals during the fourth quarter worth about $107,000. 4.27% of the stock is currently owned by institutional investors and hedge funds.
Key Stories Impacting NRx Pharmaceuticals
Here are the key news stories impacting NRx Pharmaceuticals this week:
- Positive Sentiment: HC Wainwright reiterated its Buy rating on NRx Pharmaceuticals, signaling continued confidence in the company’s longer-term prospects despite weaker near-term estimates. HC Wainwright Reiterates Buy Rating for NRx Pharmaceuticals
- Neutral Sentiment: HC Wainwright still forecasts a potential transition to profitability, with estimated EPS of $0.15 in fiscal 2028, $0.71 in 2029 and $1.14 in 2030. However, those projections remain highly dependent on successful execution and future revenue growth.
- Negative Sentiment: The analyst cut projected EPS for the third and fourth quarters of 2026 to losses of $0.43 and $0.50, respectively, from previous estimates of losses of $0.06 and $0.07. Forecasts for the first three quarters of 2027 were also reduced to losses of $0.30, $0.15 and $0.05 per share.
- Negative Sentiment: Full-year earnings estimates were sharply lowered: 2027 moved to a $0.50-per-share loss from a $0.67 profit, while estimates for 2028, 2029 and 2030 fell to $0.15, $0.71 and $1.14 from $2.49, $4.51 and $5.76, respectively. These revisions imply slower commercialization or weaker financial performance than previously expected.
NRx Pharmaceuticals Company Profile
NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.
Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.
See Also
- Five stocks we like better than NRx Pharmaceuticals
- 3 Stocks Facing New Pressure From Section 338 Tariffs on Canadian Goods
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
